65,437 trials
Schizophrenia Schizoaffective
Primary: Participants With at Least One Treatment Emergent Adverse Event (TEAE). — 10; 8; 18; 1 Number of Participants with TEAEs
Ulcerative Colitis
Primary: Number of Subjects With Treatment-emergent Adverse Events — 18; 5 Participants — p=0.2096
Aortic Valve Disease
Primary: Transvalvular Mean Pressure Gradient (mPG) — 14.1; 13.9 mmHg — p=0.0004
Hypercholesterolemia
Primary: Percent Change From Baseline in LDL-C at Week 12 — -24.7; -5.3; -23.3; -9.1 Percent change — p=<0.001
Fabry Disease
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.03 — 13; 13; 5; 2 participants
Drug Use
Primary: Pharmacokinetics Parameter — 613.21; 675.58; 807.13; 882.89 ng/mL
Type 1 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) — -0.28; -0.21 Percentage of HbA1c
Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8 · Metastatic Breast Carcinoma · Metastatic Malignant Neoplasm in the Bone
Primary: Progression-free Survival (Phase II) — 23.0; 19.5 months — p=0.36
HIV
Primary: Change in Global CFR — -.05 ratio
Necrobiosis Lipoidica
Primary: Change in Mean Necrobiosis Lipoidica (NL) Lesion Score — -2.7 score on a scale — p=0.005
Alzheimer Disease
Primary: Cerebral Blood Flow Global — -2.2 ml/100g/min — p=.002
Hereditary Angioedema
Primary: Time to Conventional Attack Treatment Use Within 12 Hours of Study Drug (Full Analysis Set) — NA; NA Time (h) — p=0.0010
Chronic Non-malignant Pain · Chronic Pain · Pain, Back
Primary: Number of Participants With Clinical Success at the 6-Month Visit — 25 Participants
Non-Cystic Fibrosis Bronchiectasis
Primary: Time to the First Pulmonary Exacerbation Over 24-Week Treatment Period — NA; NA; 189.0 days — p== 0.014
PAD
Primary: Late Lumen Loss (LLL) — -0.17 mm — p=0.000